Latest Oncology News Headlines
OBR daily E-news Oncology archives»
Study Sheds Light on Breast Cancer Drug Failure
(Reuters) Dec 4, 2008 - The most commonly used breast cancer drug may cause tumors to spread in a small number of women with low levels of a protein which makes cells stick together, British researchers said on Thursday.
read article 
UC Davis Cancer Center to Study Breast-Cancer Vaccine
(UC Davis Health System) Dec 1, 2008 - UC Davis Cancer Center researchers are launching a study of a new, experimental vaccine to determine if it can arrest or prevent breast cancer when used in conjunction with standard hormonal therapies.
read press release
50th Annual Meeting of the American Society of Hematology Will Feature Breakthrough Research in Blood Diseases
(ASH) Dec 3, 2008 - The American Society of Hematology (ASH), the world’s largest professional association of blood specialists, expects more than 20,000 attendees at the 50th ASH Annual Meeting from December 6-9, 2008, at the Moscone Center in San Francisco, CA.
read press release
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
(Novartis) Dec 4, 2008 - More than 200 abstracts from therapies across the Novartis Oncology portfolio will be presented at two December medical congresses, providing new data and profiling potential patient benefits from ongoing collaboration with the oncology community.
read press release
Cancer Research Giants Collaborate to Present the CTRC-AACR San Antonio Breast Cancer Symposium
(AACR) Dec 3, 2008 - This year marks the first San Antonio Breast Cancer Symposium to include the collaborative efforts of the American Association for Cancer Research, the Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio and the Baylor College of Medicine.
read press release
Osiris Completes Enrollment in First Worldwide Phase III Stem Cell Trial
(Forbes.com) Dec 4, 2008 - Osiris Therapeutics, Inc. announced today that it has completed patient enrollment in its Phase III pivotal trial evaluating Prochymal for the treatment of steroid-refractory acute Graft versus Host Disease (GvHD), a life threatening complication of bone marrow transplantation.
read article
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
(Forbes.com) Dec 4, 2008 - VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today that it has initiated a Phase I clinical trial of VTX-2337, a selective TLR8 agonist for the treatment of cancer.
read article
Genetic Breakdown In Fanconi Anemia May Have Link To HPV-associated Cancer
(ScienceDaily.com) Dec 3, 2008 - A genetic malfunction that causes DNA instability in people with the blood disorder Fanconi anemia may put them at high risk for squamous cell carcinomas linked to human papillomavirus (HPV), according to a study posted online ahead of print by Oncogene.
read article
Tesetaxel, a Leading Oral Taxane in Clinical Development, Receives FDA Designation as an Orphan Drug for Treatment of Patients with Advanced Melanoma
(StreetInsider.com) Dec 4, 2008 - Genta Incorporated announced today that the Company has received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, the Company's oral taxane in clinical development, has been granted designation as an "Orphan Drug" for treatment of patients with advanced melanoma.
read article
Single Cancer Cell 'Poses Danger'
(BBC News) Dec 4, 2008 - Cancer researchers may have underestimated the power of some cancers to spread and cause new tumours, say US researchers. They found just one skin cancer cell was often enough to generate a whole new tumour.
read article
NM Tech, Biomoda Win Legislative Support for Lung Cancer Screening
(CNNMoney.com) Dec 3, 2008 - The New Mexico State Legislature's Interim Tobacco Settlement Committee has recommended $730,000 in funding to continue a pilot program to screen veterans for early-stage lung cancer.
read article
Introgen Therapeutics Files for Chapter 11
(Houston Business Journal) Dec 3, 2008 - Introgen Therapeutics Inc., an Austin-based biopharmaceutical company that has most of its manufacturing operations in Houston, has filed for Chapter 11 bankruptcy protection and is looking to sell its therapeutic product portfolio.
read article
NovaRx Appoints Industry Veteran as President and COO
(MSN Money) Dec 4, 2008 - NovaRx Corporation announced today the appointment of Norrie J.W. Russell, Ph.D to the position of President and Chief Operating Officer.
read article
Jonathan Lewis, MD, PhD, Appointed to Scientific Advisory Council of the Hope Funds for Cancer...
(Forbes.com) Dec 4, 2008 - ZIOPHARM Oncology, Inc. and the Hope Funds for Cancer Research announced today that Jonathan Lewis, MD, PhD, Chief Executive and Medical Officer of ZIOPHARM, has been appointed to the Hope Funds' newly formed Scientific Advisory Council, a permanent committee of the board.
read article
Inspirational Hematologists Honored With Mentor Awards From the American Society of Hematology
(ASH) Dec 3, 2008 - In recognition of the value the American Society of Hematology (ASH) places on mentorship, ASH is proud to honor George Buchanan, MD, and Timothy J. Ley, MD, with ASH Mentor Awards, which highlight the important role mentors play in the training and professional development of hematologists early in their careers.
read press release
Ranbaxy in Marketing Pact with BioPro Pharma
(The Business Standard) Dec 3, 2008 - Ranbaxy Laboratories, India's biggest drug maker, said it is partnering US drug firm BioPro Pharmaceuticals Inc, to sell the latter’s brain tumor drug Gliadel Wafer in the country.
read article
Silence Therapeutics to Make Regulatory Filing for Lead Cancer Therapy
(Smallcapnews.co.uk) Dec 4, 2008 - Biopharmaceutical company Silence Therapeutics is planning to submit a clinical trial application (CTA) for its leading drug candidate by the end of December. The company is also in talks with several third parties over possible funding options for the new drug.
read article